Importance: Romidepsin Is A Histone Deacetylase Inhibitor Approved for the Treatm. of Cutaneous T-cell Lymphoma . Durable Responses Have Been Publ. Without Establishing A Std. Recommendation about Duration of Treatm.. Objective: to Rev. the Long-term Use of Romidepsin in Responders Who Received A Dose-sparing Regimen. Des., Setting, and Participants Retrospective Rev. of Med. Records of Patients with A Diagn. of CTCL, Includingmycosis Fungoides , Sezary Syndrome Or CTCL Not Otherwise Specified Seen at A Multidisc. Clin. at NW Univ. from 2009 until December 2014. Exposures: Doses Administered and Different Regimens of Romidepsin Were Reviewed. Main Outcomes and Measures: Duration of Treatm., Participants Rec. Dose-sparing Regimen. Results: of 47 Patients Identified, 23 Had MF, 15 Had SS, and 9 Had Other Types of CTCL. None of These 9 Achieved A Durable Response. of the Remaining 38 Patients, 17 Were Considered Long-term Responders . Nine of These Patients Received A Dose-sparing Regimen. the Median Duration of Treatm. Was 15 Months; the Frequency of Patients with SS in the Long-term Grp. Was Significantly Higher Than That of Patients with MF . Adverse Events Were Reported in 29 of 42 Patients for Whom Data Were Available. There Was No Significant Difference in the Incidence of AEs between the Short-term and Long-term Groups . Conclusions and Relevance: Decreasing the Frequency of Infusions in Patients with MF or SS Who Achieve A Response with Romidepsin Therapymay Provide A Pract. Strategy to Prolong Response.
ASJC Scopus subject areas
- Cancer Research